Sign In
Buy NVS
$148.93
+1.85 (+1.26%)
At Close: Jun 22, 2026
Novartis CEO Vas Narasimhan: ‘We really should be talking about out-of-pocket costs' in the U.S.
12:03pm, Thursday, 22'nd Jan 2026
Vas Narasimhan, CEO of Novartis, joins 'Money Movers' to discuss U.S. drug pricing, healthcare, and more.
Dynasty Wealth Management LLC Makes New $1.49 Million Investment in Novartis AG $NVS
05:20am, Wednesday, 21'st Jan 2026
Dynasty Wealth Management LLC purchased a new position in shares of Novartis AG (NYSE: NVS) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange
Novartis CEO: Confident we are shielded from any further U.S. tariffs
02:00am, Wednesday, 21'st Jan 2026
Novartis CEO Vas Narasimhan told CNBC in Davos that he believes the Swiss drugmaker is protected from any additional U.S. tariffs on Europe, citing its U.S. manufacturing footprint, inventory levels,
Sequoia Financial Advisors LLC Has $5.36 Million Stock Holdings in Novartis AG $NVS
07:15am, Tuesday, 20'th Jan 2026
Sequoia Financial Advisors LLC grew its position in Novartis AG (NYSE: NVS) by 10.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange C
Novartis could have a U.S. deal that shields it from tariffs, CEO tells CNBC
05:14am, Tuesday, 20'th Jan 2026
Swiss pharmaceutical giant Novartis expects to "not really" be exposed to tariffs by the middle of the year, CEO Vas Narasimhan told CNBC at Davos. "We also have an agreement with the US government th
Novartis expects to eliminate US tariff exposure by mid‑2026, CEO tells CNBC
05:10am, Tuesday, 20'th Jan 2026
Novartis CEO Vas Narasimhan told CNBC on Tuesday he expects the drugmaker's agreement with the U.S. government and its expanding manufacturing footprint in the country to protect it from potential tar
Novartis' Ianalumab Wins Breakthrough Therapy Tag for Sjogren's Disease
01:56pm, Monday, 19'th Jan 2026
FDA grants Breakthrough Therapy status to NVS's ianalumab for Sjogren's disease with plans for global filings starting in 2026.
Winners & Losers: The ETF Playbook to Glide Trump's Great Healthcare Plan
08:41am, Monday, 19'th Jan 2026
Trump's Great Healthcare Plan redraws healthcare winners and losers - here's how ETFs like IHE could benefit as middlemen face pressure.
Novartis (NVS) is a Top-Ranked Value Stock: Should You Buy?
10:41am, Wednesday, 14'th Jan 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zonsen PepLib Biotech and Novartis Sign Worldwide License Agreement regarding Radioligand Therapy Asset
03:07pm, Tuesday, 13'th Jan 2026
ZHUZHOU, China & BOSTON--(BUSINESS WIRE)--Zonsen PepLib Biotech Inc. (“PepLib”) today announced that it has entered into a worldwide license agreement with Novartis for an undisclosed peptide-base
First Look: Fed Probe, Bank Cap Shock, Gold Soars, Deals
07:38am, Tuesday, 13'th Jan 2026
Stock News DOJ subpoenas Fed chair spark backlash: Federal prosecutors served grand jury subpoenas to Jerome Powell over testimony on Fed HQ renovations, prompt
Novartis AG (NVS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
02:56pm, Monday, 12'th Jan 2026
Novartis AG (NVS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Novartis eyes more bolt-on acquisitions, CEO says
01:39pm, Monday, 12'th Jan 2026
Novartis will continue to do bolt-on deals and its capital allocation priorities remain unchanged, CEO Vasant Narasimhan said at a major industry conference that kicked off on Monday in San Francisco.
Tempus Shares Jump After Strong Preliminary 2025 Results
01:35pm, Monday, 12'th Jan 2026
Tempus AI (TEM) shares rose about 10% on Monday after the company filed preliminary, unaudited results showing roughly $1.27 billion in 2025 revenue.The filing
SciNeuro, Novartis sign $1.7 billion licensing deal to develop Alzheimer's drugs
09:43am, Monday, 12'th Jan 2026
Swiss drugmaker Novartis has signed a licensing deal worth nearly $1.7 billion with privately held SciNeuro Pharmaceuticals to develop potential antibody treatments for Alzheimer's disease, the biotec
